Search

Displaying 253 - 264 items out of 293 results
Press release
Iza-Bren in combination with Osimertinib Shows 100% Response Rate in EGFR-Mutated NSCLC, Phase II Study Finds
… and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 … will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more …
Press release
Patients with Lung Cancer More Likely to Feel Anxiety and Experience Treatment Delays During COVID-19 Pandemic
… other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 … will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more …
Press release
FLAURA2 Trial Shows Osimertinib Plus Chemotherapy Improves Overall Survival in EGFR-Mutated Advanced NSCLC
… and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 … covers a wide range of disciplines and unveils several research studies and clinical trial results. For more …
Press release
Ifinatamab Deruxtecan Demonstrates High Response Rate in Previously Treated Extensive-Stage Small Cell Lung Cancer: Phase 2 IDeate-Lung01 Trial
… and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 … covers a wide range of disciplines and unveils several research studies and clinical trial results. For more …
Press release
IASLC Molecular Subcommittee Lung Cancer Dataset Develops International Biomarker Snapshot
… other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 … will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more …
Press release
Ivonescimab Plus Chemotherapy Improves Progression-Free Survival in Patients with EGFR+ NSCLC Following 3rd-Generation EGFR-TKI Therapy
… and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 … covers a wide range of disciplines and unveils several research studies and clinical trial results. For more …
Press release
PALOMA-2 Study: Subcutaneous Amivantamab Every 4 Weeks Plus Lazertinib Shows High Response Rate in EGFR-Mutated NSCLC
Press release
First-Line Pembrolizumab or Placebo Combined With Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term
… other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 … will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more …
Press release
Perioperative Nivolumab May Provide Meaningful Improvement in Event-Free Survival Compared to Only Neoadjuvant Nivolumab Plus Chemotherapy for Resectable NSCLC 
… and other thoracic malignancies, attracting nearly 7,000 researchers, physicians and specialists from more than 100 … will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more …
Press release
Zidesamtinib Shows Durable Responses in ROS1 TKI Pre-treated NSCLC, Including Patients with CNS Disease and ROS1 G2032R Mutations
… and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 … covers a wide range of disciplines and unveils several research studies and clinical trial results. For more …
Press release
Study Validates AI Lung Cancer Risk Model Sybil in Predominantly Black Population at Urban Safety-Net Hospital
… and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 … will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more …
Press release
Perspective on Management of LDCT Findings on Low-Dose Computed Tomography Examinations for Lung Cancer Screening From the IASLC Early Detection & Screening Committee
… a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes … pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic …